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Abstract
Background: Nasopharyngeal carcinomas (NPC) are consistently associated with the Epstein-Barr virus
(EBV). Their malignant epithelial cells contain the viral genome and express several antigenic viral proteins.
However, the mechanisms of immune escape in NPCs are still poorly understood. EBV-transformed B-
cells have been reported to release exosomes carrying the EBV-encoded latent membrane protein 1
(LMP1) which has T-cell inhibitory activity. Although this report suggested that NPC cells could also
produce exosomes carrying immunosuppressive proteins, this hypothesis has remained so far untested.
Methods: Malignant epithelial cells derived from NPC xenografts – LMP1-positive (C15) or negative
(C17) – were used to prepare conditioned culture medium. Various microparticles and vesicles released
in the culture medium were collected and fractionated by differential centrifugation. Exosomes collected
in the last centrifugation step were further purified by immunomagnetic capture on beads carrying
antibody directed to HLA class II molecules. Purified exosomes were visualized by electron microscopy
and analysed by western blotting. The T-cell inhibitory activities of recombinant LMP1 and galectin 9 were
assessed on peripheral blood mononuclear cells activated by CD3/CD28 cross-linking.
Results: HLA-class II-positive exosomes purified from C15 and C17 cell supernatants were containing
either LMP1 and galectin 9 (C15) or galectin 9 only (C17). Recombinant LMP1 induced a strong inhibition
of T-cell proliferation (IC50 = 0.17 nM). In contrast recombinant galectin 9 had a weaker inhibitory effect
(IC50 = 46 nM) with no synergy with LMP1.
Conclusion: This study provides the proof of concept that NPC cells can release HLA class-II positive
exosomes containing galectin 9 and/or LMP1. It confirms that the LMP1 molecule has intrinsic T-cell
inhibitory activity. These findings will encourage investigations of tumor exosomes in the blood of NPC
patients and assessment of their effects on various types of target cells.
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Background
Nasopharyngeal carcinoma (NPC) is a human epithelial
malignancy which represents a major threat for public
health in several areas of the world [1]. Very high inci-
dence foci are found in south-China, especially in Guan-
dong and Guangxi provinces (25 to 40/100,000/year) but
also in other populations of South-East Asia, for example
in the Sarawak people of Borneo island [2]. Intermediate
risk areas include Philippines, Vietnam, Indonesia and
several countries of North and West Africa (incidence of 4
to 8/100,000/year). Most NPCs have minimal epithelial
maturation and are classified as undifferentiated (WHO
type III) or poorly differentiated (WHO type II). A few
cases are differentiated (WHO types I). EBV association is
constant regardless of patient origin and tumor differenti-
ation except for some rare cases of differentiated NPC
(type I) in Western countries [3]. Another striking feature
of NPC is the presence of a massive lymphoid infiltrate in
the primary tumor. This infiltrate contains mostly T lym-
phocytes and a minority of B-cells, monocytes, dendritic
cells and eosinophils. The abundant production by malig-
nant NPC cells of inflammatory cytokines, including
interleukin 1 alpha, Macrophage-Inhibitory-Protein 1
(MIP1) and CXCL10 is likely to favour the leucocyte infil-
trate [4-7].
EBV-infection in NPC cells is predominantly latent. Sev-
eral copies of the EBV genome (about 170 kb) are con-
tained in the nuclei of malignant cell. Most of the about
80 EBV genes are silenced but several immunogenic viral
proteins are consistently expressed in NPCs, including
EBNA1 (Epstein-Barr nuclear antigen 1), LMP1 (latent
membrane protein 1), LMP2 and the BARF1 protein [8-
10]. Most of these viral proteins are immunogenic in
humans. Precursors of HLA-restricted CD8 cytotoxic T-
cells (CTLs) directed to LMP1, LMP2 and EBNA1 are
present in the peripheral blood of healthy carriers [11].
Anti-LMP1 and LMP2 CTLs are detected in NPC patients'
peripheral blood [12,13].
So far the mechanisms of local immune escape in NPCs
have remained poorly understood. One clue has been
provided by studies on EBV-transformed B-cells which
release exosomes containing the EBV-encoded LMP1 in
the extra-cellular medium [14,15]. Both recombinant
extra-cellular LMP1 and exosomes from EBV-transformed
B-cells have inhibitory effects on T-cell activation and pro-
liferation [14,15]. However, until the present study, there
were no data regarding the production of exosomes by
NPC cells. Our attention was drawn to this issue by our
recent findings on the interaction of LMP1 with the cellu-
lar protein galectin 9 in NPC cells [16]. Galectin 9, a β-
galactoside-binding protein, was originally characterized
in Hodgkin's lymphoma cells and has various immu-
nomodulatory properties [17-20]. It is secreted by a mech-
anism which is so far not well understood [21]. However,
other galectins – namely galectins 1 and 3 – are known to
be secreted in association with exosomes [22,23].
This study was designed to address the hypothesis of a
possible production of exosomes containing LMP1 and/
or galectin 9 by malignant NPC cells. We report that
LMP1-positive NPC cells release HLA-class II-positive exo-
somes containing both LMP1 and galectin 9 whereas
LMP1-negative NPC cells release exosomes containing
only galectin 9. Since both LMP1 and galectin 9 are
known to have effects on immune response mechanisms,
these observations are likely to improve our understand-
ing of host-tumor relationships in NPC and possibly in
Hodgkin's disease.
Methods
NPC tumor lines and preparation of NPC cell conditioned 
media
C15 and C17 are EBV-positive NPC tumor lines perma-
nently propagated by subcutaneous passage into nude
mice [24]. Suspensions of NPC cells were obtained by dis-
persion of xenografted tumors using type II collagenase as
previously described [25]. Residual cell aggregates were
removed by filtration through a nylon cell strainer with
100 μm pores. Dispersed cells were incubated for 48 h in
24-well plates at 106 cells/well in 1.5 ml RPMI culture
medium supplemented with 1.5% fetal calf serum and 5
mM Hepes. Collected supernatants were clarified by cen-
trifugation at 300 g for 10 min and frozen at -80°C prior
to differential centrifugation. Collected 300 g cell pellets
were also stored at -80°C.
Antibodies
CS1-4 (DakoCytomation, Denmark) is a pool of 4 MoAbs
directed to the C-terminal part of LMP1; it was used under
the form of hybridoma culture supernatant, as provided
by the manufacturer [26]. Galectin 9 was detected using
an affinity-purified polyclonal antibody raised against the
C-terminal Carbohydrate Recognition Domain (CRD) of
human galectin 9 whose central motif maps at residues
287–293 [16,27]. Western blot detections of the DR α
chain and CD63 protein were performed using the
DA6.147 and TS 63 murine monoclonal antibody respec-
tively (both kindly provided by E. Rubinstein)[28,29].
Cell protein extraction and Western blot analysis
Cell pellets were dissolved in pre-chilled RIPA buffer (150
mM NaCl, 25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5%
sodium deoxycholate, 0.5% NP 40, 0.1% SDS) supple-
mented with Complete protease inhibition mixture
(Roche Molecular, Meylan, France) and sonicated.
Extracts were then clarified by centrifugation for 15 min at
10,000 g at 4°C. Protein concentration was assayed by the
Lowry method using a detergent-compatible micro-assayBMC Cancer 2006, 6:283 http://www.biomedcentral.com/1471-2407/6/283
Page 3 of 8
(page number not for citation purposes)
system (Biorad, Marnes-la-Coquette, France). Western
blotting was performed on PVDF membranes (Immo-
bilon P, Millipore, St Quentin en Yvelines, France) accord-
ing to standard protocols, using HRP-conjugated
secondary antibodies and the ECL system (Amersham, Les
Ulis, France).
Differential centrifugation of extra-cellular microparticles 
and vesicles
NPC cell conditioned media were subjected to sequential
centrifugations. Following each centrifugation step, the
pellet was collected for further analysis, and the superna-
tant was used for subsequent centrifugation. In addition
to the initial 300 g step made prior to freezing and storage,
culture supernatants were centrifuged twice at 1200 g (10
min) and then once at 10,000 g (30 min), 40,000 g (60
min) and 100,000 g (60 min) using a Beckman XL-80
ultracentrifuge with a SW41 or SW27 rotor. Pellets were
named according to their order in the separation process
from P1 (300 g) to P6 (100,000 g). When required, several
procedures of differential centrifugation were performed
in parallel. All pellets collected at the same step were
resuspended in 500 μl serum free culture medium, pooled
and pelleted again by ultracentrifugation using a TL-100
Beckman rotor (100,000 g, 60 min). Using this approach,
as much as 120 ml of culture supernatant were routinely
processed in one experiment yielding approximately 100,
80 and 180 μg proteins for P4, P5 and P6 respectively. For
Western blot analysis, representative pellets of each sepa-
ration step were dissolved in RIPA buffer (30 to 100 μl),
sonicated and clarified as indicated for cell protein extrac-
tion. An aliquot of each protein extract was used to assay
protein concentration prior to gel separation. For electron
microscopy analysis, pellets P4, P5 and P6 were sub-
merged and aggregated in the glutaraldehyde solution.
For immunomagnetic isolation of exosomes, pellet P6
was resuspended in 400 μl culture medium.
Immunomagnetic isolation of exosomes produced by NPC 
cells
A resuspended P6 pellet derived from 60 ml conditioned
medium was incubated for 5 h at 4°C, with 3.5 × 107 mag-
netic beads carrying an anti-HLA class II monoclonal anti-
body in 500 μl serum-free culture medium, under mild
agitation (Dynabeads-HLA class II, Dynal-Invitrogen).
The same type of magnetic beads carrying an irrelevant
monoclonal IgG were used as control beads (Dynabeads
Pan Mouse IgG, Dynal Invitrogen). Following the capture
step, magnetic beads were washed 4 times in 1 ml PBS. For
electron microscopy analysis, loaded beads were resus-
pended in the fixative solution. For Western blot analysis
of captured material, loaded beads were boiled 5 min in
Laemmli buffer in order to release proteins for gel separa-
tion.
Electron microscopy
Cell or microparticle pellets were fixed 1 h with 1.6% glu-
taraldehyde at 4°C, washed and fixed again in aqueous
2% osmium tetroxide, then dehydrated and embedded in
epon resin. Ultrathin sections were cut on an LKB-III ultra-
microtome, stained for contrast with uranyl acetate and
lead citrate and examined with a Zeiss EM 902 transmis-
sion electron microscope.
For visualisation of exosomes following immunomag-
netic purification, loaded beads were fixed for 1 hour at
4°C in 1.6% glutaraldehyde in phosphate Sörensen buffer
0.1 M, pH 7.3, and washed 3 × 20 min in Phosphate
buffer. They were subsequently resuspended in 4% agar,
fixed 1 hour at room temperature with 2% osmic acid
(Carlo Erba, France) and washed in water. Samples were
then dehydrated using increasing percentages of ethanol :
70% (30 min), 80% (20 min), 95% (30 min), 100% (1
hour). Finally they were included in Epon by progres-
sively mixing Epon with ethanol. Polymerisation was
made at 60°C for 48 hours. Ultrathin sections were cut
with a Reichert Ultramicrotome III and counterstained
with uranyl acetate and lead citrate.
Recombinant proteins
Full length LMP1 (LMP1) was produced in recombinant
baculovirus-infected Sf9 cells and purified by immuno-
affinity chromatography as previously described [14,30].
His-tagged LMP1dTM1 deleted of amino-acids 24–78 was
similarly produced in baculovirus and purified by nickel-
affinity chromatography. Human galectin-9 (M isoform)
was produced in E. Coli by using the pET-11a vector as
previously reported [19]. For all 3 recombinant proteins,
the absence of degradation was checked prior to func-
tional experiments by western blotting using appropriate
antibodies (data not shown).
Assessment of peripheral blood T-cell inhibition
The ability of several recombinant proteins to antagonize
peripheral blood T-cell activation and proliferation was
assessed on PBMCs (peripheral blood mononuclear cells)
stimulated with anti-CD3/anti-CD28 beads. These beads
are potent activators of peripheral blood resting T-cells
(Dynabeads CD3/CD28 T cell Expander, Dynal-Invitro-
gen). PBMCs were mixed with stimulating beads and can-
didate inhibitory proteins and then seeded in 96-well
round-bottom culture plates. In each well, 1 × 105 cells
were mixed with 17 000 beads in 200 μl RPMI medium
with 10% FCS. During the last 8 h, 3.7 × 104 Bq [3H] thy-
midine was added per well. The cells were harvested onto
fibreglass filters and [3H] thymidine incorporation was
determined by liquid scintillation counting.BMC Cancer 2006, 6:283 http://www.biomedcentral.com/1471-2407/6/283
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Results
LMP1 and galectin 9 associate with extra-cellular particles 
and vesicles released by NPC cells
So far there has been no experimental system allowing in
vitro growth of NPC cells derived from clinical specimens.
However, two xenografted NPC tumor lines were
obtained in our laboratory and have been extensively
characterized [24,31]. Both are EBV-positive. One
xenograft called C15 is the only known NPC tumor line
having spontaneous LMP1 expression while the other
called C17 has no LMP1 expression. Cells derived from
these xenografts were used for short term culture in vitro
and preparation of conditioned culture supernatants.
These supernatants were subjected to differential centrifu-
gation in order to collect extra-cellular particles or vesicles
in distinct pellets on the basis of their sedimentation char-
acteristics. Cell debris were cleared by 2 centrifugations at
1200 g (pellets P2 and P3) prior to sedimentation of
microparticles and vesicles at 10,000 g, 40,000 g and
100,000 g, yielding pellets P4, P5 and P6 respectively. All
pellets were analysed by western blotting. As shown in
Figure 1A, LMP1 and galectin 9 were detected in P4, P5
and P6 from the C15 supernatant supporting the idea that
both proteins were associated with a variety of extra-cellu-
lar particles and vesicles. In the same way, galectin 9 was
detected in association with various types of pelleted
material derived from the C17 culture supernatant (as
expected, no LMP1 was detected in the C17 pellets, data
not shown). Because exosomes are known to have impor-
tant functions in cell communications, our subsequent
investigations were focused on this category of extra-cellu-
lar vesicles. One potential difficulty was the production by
the C15 cells of abundant retroviral particles resulting
from post-xenograft infection by a murine xenotropic ret-
rovirus [24]. Retroviruses are known to mimic several
physical and biochemical properties of exosomes, includ-
ing transport of cellular proteins in their envelope. There-
fore pellets P4, P5 and P6 were analyzed by electron
microscopy to monitor retrovirus contamination (Figure
1B). Retroviral particles were quite abundant in P4, still
visible in P5, but virtually absent in P6. On the other
hand, there were clues that at least a fraction of exosomes
were collected in P6. Small vesicles of about 70 nm diam-
eter were visualized in this pellet despite the background
of amorphous material. In addition, the HLA class II DRα
chain and the CD63 protein which are common exosomal
markers were detected by Western blotting in this fraction
(Figure 1C) [32].
Small NPC vesicles carrying LMP1 and/or galectin 9 
display essential characteristics of exosomes
To confirm that at least a fraction of the small vesicles
recovered in P6 were typical exosomes we intended to
purify these elements by immunomagnetic capture. One
major characteristic of exosomes released by immune
effector cells is their exhibition of HLA class II molecules
whose extra-cellular domain is accessible on their external
face [32]. Because we have previously shown that NPC
cells have intense, constitutive expression of HLA class II
molecules, their exosomes were expected to carry and dis-
play these molecules and therefore to be captured using
anti-class II antibodies bound to magnetic beads [24].
Indeed this capture process was very efficient (Figure 2).
P6 pellets derived from C15 and C17 cell conditioned
medium were resuspended and incubated with either
anti-HLA class II coated beads or control beads. Vesicles
with a uniform shape and a size of about 70 nm in diam-
eter were specifically adsorbed on anti-HLA class II beads
and identified as exosomes. Protein analysis of bead-
Association of LMP1 and galectin 9 with various types of  extra-cellular particles released by C15 NPC cells Figure 1
Association of LMP1 and galectin 9 with various 
types of extra-cellular particles released by C15 NPC 
cells. A) Western blot analysis of the pellets obtained by dif-
ferential centrifugation of C15 and C17 cell conditioned 
medium (14 μg/lane). B) Electron microscopy of 3 sequential 
pellets obtained by differential centrifugation of C15 cell con-
ditioned medium. P4 (10,000 g), P5 (40,000 g) and P6 
(100,000 g) are shown at magnification 90,000, 90,000 and 
135,000 respectively. Arrowheads point to retroviral parti-
cles (P4 and P5). White arrows point to vesicles of 70 nm 
diameter compatible with exosomes (P6). The apparent het-
erogeneity of vesicle sizes in pellet P6 results in a large 
extent from the fact they are seen in a planar section with 
some vesicles being cut tangentially. C) Western blot detec-
tion of the DRα chain and CD63 protein in C15 cells (30 μg) 
and P6 (14 μg) extracts (for CD63, gel separation was done 
in non-reducing conditions as previously reported [29]).BMC Cancer 2006, 6:283 http://www.biomedcentral.com/1471-2407/6/283
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bound material confirmed the presence of LMP1 in C15
exosomes. As expected it was absent in C17 exosomes.
Galectin 9 was contained in exosomes from both tumor
lines although less abundant in C17 exosomes; an obser-
vation that is consistent with the lower amount of galectin
9 in C17 compared to C15 cells [16].
Impact of recombinant LMP1 and galectin 9 on peripheral 
blood T-cell proliferation induced by CD3-CD28 cross-
linking
Both B-cell derived exosomes and purified recombinant
LMP1 were shown to inhibit the proliferation of periph-
eral blood T-cells induced by antigen, mitogen or CD3-
CD28 stimulation whereas galectin 9 is known to modu-
late T-cell maturation and functions in various ways
[14,15,18-20]. Because both LMP1 and galectin 9 were
carried by C15 exosomes, we intended to assess the T-cell
inhibitory power of recombinant LMP1 by itself or in
combination with recombinant galectin 9. Resting PBMC
were treated with CD3-CD28 cross-linking to activate T-
cells and simultaneously by recombinant LMP1 or galec-
tin 9 at increasing concentrations. As previously reported,
a marked inhibition of T-cell proliferation resulted from
the addition of wild-type recombinant LMP1 (Figure 3).
Fifty per cent inhibition was achieved at a concentration
as low as 10 ng/ml (IC 50 = 0.17 nM). In contrast, a
mutant form of recombinant LMP1 (LMP1dTM1),
deleted of amino-acids 24–78, had no inhibitory effects.
Immuno-magnetic isolation of exosomes secreted by EBV-positive NPC cells expressing LMP1 (C15) or not (C17) Figure 2
Immuno-magnetic isolation of exosomes secreted by EBV-positive NPC cells expressing LMP1 (C15) or not 
(C17). Upper panel: electron-microscopy examination of magnetic beads following incubation with low density vesicles 
derived from C15 and C17 cell culture supernatant (× 90,000). The beads have a 4.5 μm diameter. Numerous vesicules of 
about 70 nm in diameter are bound to magnetic beads coated with anti-HLA II antibodies. In contrast Ig-coated beads did not 
yield any bound exosomes. Insert : One exosome at high magnification with a typical 7–8 nm lipid bilayer (× 135,000). Lower 
panel: Western blot analysis of bead-bound proteins. LMP1 is contained in C15 but not C17 exosomes whereas galectin 9 is 
contained in exosomes from both tumor lines, although less abundant in C17 exosomes. In addition to exosome material, light 
Ig chains are released from control beads as well as HLA class II beads confirming that both types of beads have been subjected 
to the same conditions of elution (in contrast heavy chains covalently bound to the beads are not released by boiling in gel 
loading buffer).BMC Cancer 2006, 6:283 http://www.biomedcentral.com/1471-2407/6/283
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An inhibitory effect was also recorded for galectin 9 by
itself but a much higher concentration was required : 1.6
μg/ml for fifty per cent inhibition (IC50 = 46 nM). When
both molecules were used in combination, at suboptimal
concentrations, we could see no synergy in T-cell inhibi-
tion (Figure 3).
Discussion
Malignant as well as non-malignant cells can release sev-
eral types of vesicles and microparticles [33,34]. Most of
these elements are thought to be shed directly from the
plasma membrane. In contrast typical exosomes derive
from late endosomal structures called multivesicular bod-
ies and have distinctive morphological and biochemical
characteristics, including a high content of HLA class II
molecules and tetraspanins like CD63 [32]. By differential
centrifugation and immunomagnetic capture, we have
isolated vesicles derived from NPC cells displaying two
major features of exosomes : a diameter in the range of
30–90 nm (70 nm) and surface expression of HLA class II
molecules. We have demonstrated that exosomes derived
from LMP1-positive NPC cells contain both LMP1 and
galectin 9, whereas those derived from LMP1-negative
cells contain only galectin 9. For technical reasons we
chose to capture exosomes only from the P6 fraction
(100,000 g pellet), but obviously galectin 9 and LMP1
were abundant in the P4 (10 000 g) and P5 (40 000 g)
fractions. They are probably associated to additional types
of extra-cellular vesicles possibly including exosomes of
larger size and – in the case of the C15 supernatant – ret-
roviral particles. Nevertheless this is the first demonstra-
tion that NPC cells release LMP1 and galectin 9 and that
these proteins are at least in part associated with typical
exosomes. Release of galectin 9 in the extra-cellular
medium has long been known in other cellular models
but, to our knowledge, this is the first demonstration that
galectin 9 can be carried by exosomes as previously
reported for galectins 1 and 3 [21-23].
Both LMP1 and galectin 9 have proven immunomodula-
tory properties. Soluble recombinant LMP1 has strong
inhibitory effects on the activation of human resting T-
cells in vitro. The same inhibition is obtained using short
peptides containing a critical inhibitory motif derived
from LMP1 first transmembrane segment (LALLFWL –
amino-acids 34–40). This motif has a strong homology
with a retroviral motif also known to antagonize T-cell
activation [14]. In figure 3, the lack of T cell inhibition by
LMP1dTM1 which is deleted of the critical inhibitory
motif is consistent with these previous observations. Sev-
eral immunomodulatory activities of galectin 9 have been
reported. Recombinant galectin 9 induces maturation of
human dendritic cells with enhanced differentiation of
Th1 lymphocytes [19]. On the other hand, galectin 9
induces apoptosis of human T-lymphocytes, especially
Inhibition of anti-CD3/anti-CD28-induced proliferation of  peripheral blood T-cells by recombinant LMP1 and galectin 9 Figure 3
Inhibition of anti-CD3/anti-CD28-induced prolifera-
tion of peripheral blood T-cells by recombinant 
LMP1 and galectin 9. Proliferation was measured by [3H] 
thymidine incorporation after a 3-day culture of PBMCs stim-
ulated by anti-CD3/anti-CD28 beads. Recombinant 
LMP1dTM1 is deleted of residues 24–78. In the experiment 
depicted in the bottom panel, LMP1 and galectin 9 were used 
at 10 ng/ml (0.17 nM) and 0.5 μg/ml (14 nM) respectively 
whereas in the control experiment, PBMCs were stimulated 
by CD3/CD28 cross-linking in the absence of additional rea-
gents. Each of these experiments were performed at least 3 
times using PBMCs from at least 2 donors.BMC Cancer 2006, 6:283 http://www.biomedcentral.com/1471-2407/6/283
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pre-activated CD4 lymphocytes [18]. Finally, in mice,
galectin 9 has been shown to induce apoptosis of mature
Th1 cells through binding and activation of the Tim-3 lig-
and [20]. In our experimental system, we have found no
synergy between soluble LMP1 and galectin 9. Our data
are consistent with the idea that LMP1 has a broad anergic
effect on various T-cell populations whereas galectin 9 can
induce inhibitory effects on more restricted populations.
In any event, in the future, it will be necessary to investi-
gate the effects of LMP1 and galectin 9 in the context of
exosomes and not only as soluble molecules.
Because of the immunomodulatory properties of LMP1
and galectin 9, our observations are expected to have a
major impact in the elucidation of host-tumor relation-
ships in NPC patients. Indeed the emergence of a malig-
nant process producing several immunogenic viral
proteins in a context of local inflammation and heavy leu-
cocytic infiltration remain one major paradox of this dis-
ease. It is even more surprising since previous reports
indicate that NPC cells retain a functional antigen present-
ing machinery [12,35]. This suggests that NPC immune
escape is promoted by specific features of the tumor
microenvironment. To address this problem several
groups have investigated local production of immuno-
suppressive cytokines but without significant results. For
example production of Fas ligand by NPC cells is not fre-
quently observed at early stages of the disease [36]. TGF-
beta gene is not expressed at a higher level in tumor tissue
compared to normal adjacent mucosa [5]. Studies on IL-
10 have yielded conflicting results [5,37,38]. In this con-
text, it will be extremely important to confirm that exo-
somes carrying LMP1 and/or galectin 9 are released by
malignant NPC cells in situ. Moreover, alterations of sys-
temic immunity has been reported in NPC patients
[39,40]. It will be important to investigate the presence of
LMP1 and/or galectin 9 containing exosomes in the bio-
logical fluids of these patients. Similar hypotheses might
also be relevant to Hodgkin lymphomas where galectin 9
expression has been initially reported and which is associ-
ated to EBV in about 50% of the cases with consistent and
intense expression of LMP1 [17,41].
Conclusion
This study demonstrates that NPC cells can release HLA
class-II positive exosomes containing galectin 9 and/or
LMP1. Along with galectins 1 and 3, galectin 9 should
now be included in the list of galectins which can be car-
ried by exosomes. This report confirms that recombinant
LMP1 has intrinsic T-cell inhibitory activity although no
synergy between recombinant galectin 9 and LMP1 were
found in T-cell inhibition experiments. One important
aim in the future will be to assess on various target cells
the biological activity of extra-cellular galectin 9 and
LMP1 when they are inserted in exosomes. Another
important aim will be to investigate the presence of galec-
tin 9/LMP1-positive exosomes in the blood and biological
fluids of NPC patients.
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